The use of spirocyclic scaffolds in drug discovery  by Zheng, Yajun et al.
Bioorganic & Medicinal Chemistry Letters 24 (2014) 3673–3682Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclBMCL DigestThe use of spirocyclic scaffolds in drug discoveryhttp://dx.doi.org/10.1016/j.bmcl.2014.06.081
0960-894X/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Tel.: +1 2154612023.
E-mail address: yzheng@vitaerx.com (Y. Zheng).Yajun Zheng ⇑, Colin M. Tice, Suresh B. Singh
Vitae Pharmaceuticals Inc., 502 West Ofﬁce Center Drive, Fort Washington, PA 19034, United States
a r t i c l e i n f oArticle history:
Received 15 April 2014
Revised 17 June 2014
Accepted 27 June 2014




Drug discoverya b s t r a c t
Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increas-
ingly utilized in drug discovery. In this brief review, we highlight selected examples from the primary
medicinal chemistry literature during the last three years to demonstrate the versatility of spiro scaffolds.
With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are
likely to be used more frequently in drug discovery.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).One widely used strategy in drug design is to rigidify the ligand
conformation by introducing a ring.1 The resulting cyclic analog
will suffer a reduced conformational entropy penalty upon binding
to a protein target. In addition to ring fusion, conformational
restriction can also be imposed by introduction of a spiro-ring
fusion. Spiro compounds are molecules containing two rings with
just one shared atom (the spiroatom). Spiro rings such as spiroke-
tals are present in numerous natural products;2 simple spiroketals
are known insect pheromones. A small number of spiro containing
drugs has been investigated during the last several decades;3 a few
examples are shown in Figure 1. Recent progress on new synthetic
routes to spiro building blocks will facilitate incorporation of spiro
scaffolds into more pharmaceutically active molecules. Spiro con-
taining systems not only have greater three-dimensionality than
ﬂat aromatic compounds, but also introduce structural novelty
for patentability. Even though both spirocyclic and ﬂat aromatic
rings can impact ligand binding entropy, it has been suggested that
compounds with too many ﬂat rings have suboptimal physical
properties and are less likely to be successfully developed as
drugs.4 As a result, spiro compounds have increasingly appeared
in the recent literature.5
In this review, selected examples from medicinal chemistry lit-
erature published within the past three years (2011- March 2014)
will be presented to illustrate the utility of spirocyclic scaffolds in
drug discovery.
3-Membered spirocyclic systems: Cyclopropane and oxirane can
be incorporated into spiro scaffolds, for example compounds 1–6
(Fig. 2). Even though the N–H and N–Me forms of aziridines arepresent in a number of bioactive natural products such as mito-
mycins, it is generally difﬁcult to construct such aziridines from
unfunctionalized oleﬁns. A recent report of a facile synthetic route
to N–H and N–Me aziridines will enable their incorporation into
drug molecules.6
Free fatty acid receptor 1 (FFA1, or GPR40), is a GPCR highly
expressed in pancreatic b-cells and is considered to be an attractive
target for type 2 diabetes. Two spiro FFA1 agonists have been
reported recently.7,8 Compound 1a (AM-5262) is a full agonist of
FFA1 with an EC50 of 0.081 lM.7 As compared to the unconstrained
early lead AM-1638 (1b), the introduction of the spiro constraint
improved the potency for FFA1 by twofold, and enhanced the off-
target selectivity when tested at 10 lM against a panel of 101
GPCRs, ion channels, transporters, and enzymes. AM-5262 demon-
strated >90% inhibition of only one member of this panel, while the
non-spirocyclic AM-1638 inhibited four targets. AM-5262 has rea-
sonable rat PK (half-life = 4.2 h; clearance = 0.25 L/h/kg; F% = 28)
and showed enhanced glucose stimulated insulin secretion and
improved glucose homeostasis in vivo. Astellas disclosed another
FFA1 agonist, compound 2 (AS2575959), and described its effect
on glucose metabolism and potential synergy with a dipeptidyl pep-
tidase-IV (DPP-IV) inhibitor, sitagliptin.8 The demonstrated synergis-
tic effect on the glucose dependent insulin secretion and GLP-1
concentration increase appears to be the ﬁrst between a FFA1 ago-
nist and a DPP-IV inhibitor. The structural resemblance between
the Amgen and Astellas compounds (1a and 2, respectively) is quite
apparent. However, the spiro ring fusion patterns are different.
Sudemycin D6 (3), was shown to be a modulator of pre-mRNA
splicing with potent cytotoxic activity in various tumor cell lines
(IC50 = 39 nM for SK-MEL-2, 22 nM for JeKo-1, 50 nM for HeLa,
and 81 nM for SK-N-AS cell lines).9 Compound 4 is a potent,


































































































































Figure 2. Spirocyclic compounds incorporating 3-membered rings.
3674 Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682against genotype 1a replicon) from Gilead.10 It has a plasma half-
life of 37–45 h in healthy volunteers, and phase 2 trials showed 4
to be very safe and well tolerated. Recently, a novel spiro antago-nist (5) of histamine-3-receptor (H3R) was reported.11 Compound
5 is potent against H3R (IC50 = 8.3 nM; hERG >33 lM) and selective
over a panel of 144 secondary pharmacological receptors.
Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682 3675Spirocyclic nucleoside analog 6 was reported to demonstrate
signiﬁcant antiviral activity against HCV (EC50 = 0.273 lM, and
0.368 lM for genotypes 1A and 1B, respectively).12
4-Membered spirocyclic systems: Compounds 7–17 (Figs. 3 and 4)
are recent examples of spirocyclic scaffolds incorporating 4-mem-
bered rings. Among nucleoside modiﬁcations that have been
explored by Pharmasset and Janssen as anti-HCV compounds are
20-spirocyclic ethers.13,14 Spirocyclic 20-oxetane guanosine triphos-
phate 7 inhibits both wild-type and S282T mutant RNA polymer-
ase, NS5B, with an IC50 of 9.5 lM against wild-type NS5B
polymerase and 10.4 lM for S282T mutant.13 Phosphoramidate
prodrugs of 20-deoxy-20-spirooxetane cytidine and uridine (e.g.,
8) exhibited EC50 values from 0.2 lM to >98 lM in the Huh7-
replicon cell line without apparent cytotoxicity.14
In recent years, oxetanes have attracted attention in the drug
discovery community.15 HCV NS3 protease inhibitors represent
another type of therapy for treatment of hepatitis C viral infection.
Spiroazetidine 9 is a less potent analog of boceprevir with an
IC50 = 0.8 lM against NS3 protease.16
Spirooxetane 10 is a potent inhibitor of RSV (respiratory syncy-
tial virus) A polymerase (replicon EC50 = 10 nM).17 Additional
investigations indicated that 10 was rapidly absorbed into the sys-
temic circulation following intratracheal dosing. Therefore insufﬁ-
cient compound was retained in the lung and bronchoalveolar
lavage ﬂuid, suggesting further improvement is still needed.
Compounds 11–13 (Fig. 4) are 2,7-diazaspiro[3,5]nonane
inverse agonists of ghrelin receptor (GR), a GPCR target that plays
a role in obesity and glucose homeostasis.18 Compound 11 (hGR
IC50 = 4.6 nM) has an undesired off-target effect; speciﬁcally it
demonstrated muscarinic acetylcholine receptor (mAChR) M2
activity (pKi = 6.57 (or Ki = 269 nM)).18a Cyclization near the azeti-
dine nitrogen yielded 12 (hGR pKi = 8.2 (or Ki = 6.3 nM)) with
improved selectivity over mAChR M2 (pKi = 4.85 (or Ki = 14125.4 -
nM)) as well as high receptor occupancy.18b A further optimized
compound (13, PF-5190457, pKi = 8.36 (or Ki = 4.4 nM)) showed a
better balance of receptor activity and off-target selectivity (M2
Kb/ghrelin receptor Ki ratio of 266).18c
Compound 14 is an inhibitor of fatty acid amide hydrolase (hFAAH
apparent IC50  = 8 nM).19 Spiro compound 15 is a very potent inhib-
itor (IC50 = 3.3 nM) of histone methyltransferase G9a with excellent
selectivity of >1000-fold over 21 other methyltransferases.20
Structure-based design has been successfully applied to


































Figure 3. Spirocyclic compounds cAPP-cleaving enzyme 1), which has been a subject of investigations
as a target for Alzheimer’s disease.21 The design of potent BACE1
inhibitors which are also brain penetrant has been a major chal-
lenge for many research teams. Amgen reported a series of hydoxy-
ethylamine (HEA) based BACE1 inhibitors (e.g., 16 and 17) that
lower Ab levels in rat brains after oral administration.22,23 Com-
pound 16 is a potent (IC50 = 5.5 nM in FRET assay, 9.6 nM in cell),
permeable inhibitor with low rat P-glycoprotein (P-gp) efﬂux ratio
of 1.7. These compounds are also potent CYP3A4 inhibitors (e.g.,
CYP3A4 IC50 for 17 is 50 nM);22 potent CYP3A4 inhibition is gener-
ally undesirable for a drug molecule.
5/5 and 5/6 spiro-ring fused systems: The majority of the spirocy-
clic scaffolds described in the literature incorporate 5- and 6-
membered ring systems. Using an X-ray based fragment screen,
scientists at Pﬁzer identiﬁed BACE1 inhibitors with a spiropyrroli-
dine scaffold; further structure-based optimization led to a 1 lM
inhibitor (18, Fig. 5).24 Compound 19 was reported to be a potent
antagonist (IC50 = 8.6 nM) of the protease activated receptor 1
(PAR1), which plays an important role in thrombin mediated plate-
let aggregation.25 However, the current structures (19 and analogs)
were metabolized quickly and further improvements are required.
The racemic 1-thia-4,7-diaza-spiro[4.4]nonane-3,6-dione con-
taining compound 20 is a potent antagonist of 5-hydroxytrptamine
6 (5-HT6) with Ki of 26 nM. The more potent enantiomer of 20 had
a Ki of 15 nM against 5-HT6 with good selectivity over other
members of the serotonin family.26
Small molecule protein/protein interaction inhibitors which
disrupt the MDM2/p53 interaction have been a subject of clinical
investigations.27 Wang’s group at the University of Michigan has
discovered a class of spirooxindole-based inhibitors.28 Their opti-
mization efforts led to the discovery of compound 21 (MI-888),
which showed remarkable activity in xenograft models of human
cancer after oral administration and appears to be the most efﬁca-
cious MDM2 inhibitor (Ki = 0.44 nM) reported so far. Spirooxin-
dole-3,30-thiazolidine containing compound 22 (IC50 = 40 nM)
also showed interesting activity in human tumor cell lines.29
Compound 23 represents another class of inhibitors based on the
spiroisoxazoline oxindole scaffold; the disruption of the p53/
MDM2 complex was demonstrated in a live-cell biomolecular ﬂuo-
rescence complementation assay.30 Compounds 24 (RO2468) and
25 (RO5353) are potent (IC50 = 6 nM and 7 nM, respectively), orally
active MDM2/P53 antagonists from Roche that are clearly structur-
















































































































































Figure 5. Compounds containing 5/5 spiro-ring fusions.
3676 Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682with a heterocycle (chlororopyridine in 24 and chlorothiophene in
25, respectively).31
Spirohydantoin BMS-688521 (26, Fig. 6) is an antagonist
(IC50 = 2.5 nM) of the interaction between integrin LFA-1 (leuko-
cyte function associated antigen-1) and ICAMs (intercellular adhe-
sion molecules) and has been advanced into clinical trials.32
XEN402 (27) is a spirooxindole containing inhibitor of the
Nav1.7 ion channel which is in clinical trials for treatment of pain
in patients with congenital erythromelalgia.33 Spiroindoline 28 is
a SYK kinase inhibitor with an IC50 of 0.189 lM and good selectiv-
ity over a panel of kinases.34 A structurally related compound (29)
was reported to be a probe for the human (EC50 of 3.2 lM) and rat
muscarinic M1 receptor subtype.35 Compound 30 is a new antago-
nist of the CGRP receptor (Ki = 0.04 nM, P-gp efﬂux ratio of 1.4), a
GPCR target for migraine.36 Compound 31 is a potent p38a kinase
inhibitor (IC50 = 1.8 nM) with good bioavailability in rat (65%).37Compound 32 from GlaxoSmithKline is an analog of 4 with a
different spiro ring fusion. Compound 32 is a potent HCV NS5A
inhibitor (pEC50 = 10.4 (EC50 = 39.8 pM) for NS5A gt1A).38 Com-
pound 33 (SMU-B, Fig. 7), structurally related to 31, has been
reported to be a potent, orally available dual c-Met (IC50 = 1.87 nM)
and ALK (IC50 <0.5 nM) inhibitor.39 SMU-B demonstrated signiﬁ-
cant tumor growth inhibition in GTL-16 human gastric carcinoma
xenograft models.
The discovery of sodium glucose cotransporter 2 (SGLT2) inhib-
itor, tofogliﬂozin, for treatment of type 2 diabetes was reported by
Chugai.40 Compound 34 is highly selective for SGLT2 (IC50 of
2.9 nM for hSGLT2 vs 8444 nM for hSGLT1). Tofogliﬂozin is cur-
rently in phase 3 clinical trials. Compound 35 is a potent inhibitor
of 11-b HSD1 (IC50 = 1.1 nM).41 A spiro scaffold has been used to
mimic Pro-Leu-Gly-NH2 as shown in compound 36, which behaves
















































































































































Figure 7. Compounds with 5/6 spiro-ring fusions.
Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682 3677GPR119 agonists have provided another mechanism to regulate
glucose homeostasis and treat type 2 diabetes. Based on virtual
screening and combinatorial chemistry follow-up, scientists at
Boehringer Ingelheim discovered a novel class of GPR119 agonists,
exempliﬁed by 37 (EC50 = 93 nM).43 Afﬁnity selection mass spec-
trometry (AS-MS) was used by scientists at Merck to discover some
spirooxindoles as inhibitors of hypoxia-inducible factor prolyl
hydroxylase 1–3 (HIF PHD1-3).44 Subsequent optimization yielded
spirohydantion 38 (PHD1 IC50 = 0.2 nM; PHD2 IC50 = 0.2 nM; PHD3
IC50 = 1.6 nM; hERG binding of 22 lM; and CYPs >50 lM) as a pre-
clinical candidate for treatment of anemia.
Phospholipase D (PLD) is an antipsychotic target. ML298 (39
where R = H, X = Y = F) is a selective PLD2 inhibitor (PLD1 IC50
>20,000 nM, PLD2 IC50 = 355 nM) while a close analog of ML298
(ML299, 39 where R = CH3, X = Br, Y = H) is dual PLD1/PLD2
inhibitor (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM).45 A spiropiperidi-
neamide-based human b-tryptase inhibitor was reported by scien-
tists from Sanoﬁ-Aventis (40). This potent inhibitor 40 (Ki = 15 nM)also exhibited excellent metabolic stability without signiﬁcant
hERG channel inhibition.46 Spiroimidazolone containing compound
41 was reported to be a potent and selective glucagon receptor
antagonist (hGCGR cAMP IC50 = 46 ± 12 nM; hGLP-1R cAMP IC50
>10,000 nM).47 At 30 mg/kg, 41 showed a signiﬁcant glucose-
lowering effect in a mouse model of type 2 diabetes.
CCR1 is a chemokine receptor that is believed to play an impor-
tant role in chronic inﬂammatory diseases. Astra-Zeneca described
compound such as 42 (Fig. 8) that are potent antagonists of human
(IC50 = 1.8 nM) as well as rat CCR1 (IC50 = 16 nM).48
A number of 5/6 spirofused BACE1 inhibitors have been
reported over the last three years. Aminooxazoline-based BACE1
inhibitor 43 from Amgen displayed good potency against BACE1
in both enzyme (IC50 = 8 nM) and cellular (IC50 = 36 nM)
assays; it also showed good selectivity over cathepsin D
(IC50 = 4470 nM).49 Compound 43 is brain penetrant, and a single
oral 30 mg/kg dose resulted in signiﬁcant CNS Ab40 reduction in






















































































Figure 8. Further examples with 5/6 spiro-ring fusions.
3678 Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–368243 can be replaced by a saturated ring as shown in 44.50 Spiropyrr-
olidine 45 exhibited good BACE1 inhibition (IC50 = 29 nM).51 The
aminohydantoin 46 is also a potent BACE1 inhibitor (IC50 = 48 nM)
and reduced CSF Ab in rodents and monkey.52 Unlike the above
mentioned HEA based BACE1 inhibitors (16 and 17, Fig. 4) which
bind to the ﬂap closed conformation of BACE1, both the aminoox-
azoline and aminohydantoin based inhibitors bind to the ﬂap open
BACE1 conformation. Compound 47 (Fig. 8) is spirocyclic sulfamide
BACE1 inhibitor from Pﬁzer (IC50 = 0.10 lM).53
Spiropiperidine based compound 48a from BMSwas reported to
be a potent, orally available P2Y1 antagonist (FLIPR IC50 = 2.6 nM;
solubility of 4 lg/mL) and demonstrated a robust antithrombotic
effect in the rat thrombosis and hemostasis models.54a Further
optimization led to 48b (FLIPR IC50 = 0.12 nM; solubility of
680 lg/ml),54b which is more efﬁcacious than 48a. Spiroquinucli-
dines and derived analogs (e.g., 49 and 50) are known a7 nicotinic
acetylcholine receptor modulators, which have been reviewed
recently.55 TRV130 (51) is a novel agonist of G protein l opioid
receptor (pEC50 = 8.1 (or EC50 = 7.9 nM)) discovered by Trevena;56
it is now in clinical trials for treatment of acute severe pain.
Compound 52 exhibited potent inhibition of renin (IC50 = 0.5 nM),
a target for hypertension (Fig. 8).57
The two orexin receptor subtypes (OX1R and OX2R) are targets
for treatment of insomnia. Spiropiperidine 53 is a potent and selec-
tive orexin-2 receptor (OX2R) antagonist (IC50 = 3.3 nM; 450-fold
selective against OX1R).58 Compound 54 is a potent neuropeptide
Y5 receptor antagonist (Ki = 1 nM) with good metabolic stability
in human (Clint <6 ml/mg/kg) and rat (Clint <25 ml/mg/kg) micro-
somes.59 However, it failed to show efﬁcacy in a diet-induced
obese rat model. Compound 55 represents a novel class of mGluR5
allosteric modulators.60 Compound 55 is potent (IC50 = 23 nM), and
brain penetrant, and has shown efﬁcacy in the mouse marble bury-
ing test, which is generally used as an indicator of potential anxio-
lytic activity.60 Spiropiperidine compound 56 has been developedas positron emission tomography imaging agent for the r1 recep-
tor (Ki = 0.79 nM).61 Interestingly, a spiro inﬂuenza virus A neur-
aminidase inhibitor (57) was discovered by Pinto and coworkers
during synthetic follow-up of a carbocyclic analogues of zanamivir
(Fig. 9).62
Lipid synthesis plays an important role in obesity, type 2 diabe-
tes, and cancer. As the ﬁrst committed step in the pathway to fatty
acids, acetyl CoA carboxylase (ACC) has been intensively investi-
gated.63 Compound 58 is a potent acetyl-CoA carboxylase (ACC)
inhibitor discovered by Takeda (IC50 = 32 nM for ACC1 and
5.4 nM for ACC2).64a Further optimization generated compound
59 (ACC1 IC50 = 21 nM; ACC2 IC50 = 4.9 nM), which is orally bio-
available and signiﬁcantly decreased the values of the respiratory
quotient in rats.64b
6/6 Spiro-ring systems: Based on screening of an in-house com-
pound collection and subsequent optimization, Pﬁzer scientists
identiﬁed some spiroketone-derived ACC inhibitors.65 Further
optimization led to spirolactam 60 (Fig. 10), a pre-clinical candi-
date for type 2 diabetes.65 Compound 60 is potent for both ACC1
(IC50 = 10 nM) and ACC2 (IC50 = 4 nM) and has good in vivo meta-
bolic stability (HLM <8 lL/min/mg).
Compound 61 from Novartis is a selective antagonist of hOX2R
(pKi = 7.85 (Ki = 14.1 nM) vs 6.29 (Ki = 512.9 nM)) for hOX1R), and
induced sleep in mice.66
Compound 62 is a r receptor agonist with modest selectivity
over r2 (r1 Ki = 0.55 nM, r2 Ki = 109 nM).67 Further optimization
of the fused ring and the N-substituent led to a more selective
compound (63) (r1 Ki = 1.1 nM with a r1/r2 selectivity ratio of
>900).68 Based on the previously reported anti-trypanosome activ-
ity of amantadine and rimantadine (anti-inﬂuenza A drugs) and
the presence of essential metalloenzymes in trypanosomatid, Fytas
et al. designed some novel N-hydroxyamides that showed excel-
lent trypanocidal activity as exempliﬁed by compound 64 (Trypan-


















































































































































Figure 10. Compounds containing 6/6 spiro-ring fusions.
Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682 3679Compound 65 is a potent, orally bioavailable histone deacetylase
(HDAC) inhibitor (IC50 = 0.121 lM), and showed tumor growth
inhibition in an HCT-116 murine xenograft model.70
Spirobenzopyranpiperidine 66 is a potent and selective
histamine-3 receptor (H3R) antagonist (hH3 Ki = 7 nM, rH3
Ki = 17 nM).71 The bioavailability of 66 and its analogs is rather
low; further optimization is required. Compound 67 was reported
to be a potent inhibitor of soluble epoxide hydrolase (IC50 = 1.1
nM) with good bioavailability as well as some renal protectiveeffect in a rat model.72 Compound 68 inhibits a number of pro-
tein kinases73 and 69 is an orally available inhibitor of MK2
(EC50 = 7.4 nM).74
Peptidomimetic 70 is a dual neurokinin 1 (NK1, pKi = 8.6
(Ki = 2.5 nM)) and neurokinin 3 (NK3, pKi = 8.1 (Ki = 7.9 nM)) recep-
tor antagonist.75
7-Membered spirocyclic systems: Four spiro compounds which
incorporate a seven membered ring have been reported (Fig. 11).



































Figure 11. Compounds containing a 7-membered spirocyclic scaffolds.
3680 Y. Zheng et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3673–3682desaturase-1 (SCD1), a therapeutic target for metabolic disorders
and other indications.78 Compound 71 is potent against mSCD1
(IC50 = 8 nM) with a reasonable PK proﬁle and also showed a mod-
erate reduction of the plasma desaturation index 4 h after oral dos-
ing at 30 mg/kg. However, at higher doses over an extended period,
some target-related side effects were observed. Compound 72
inhibited human SCD1 with an IC50 of 10 nM.77
Compound 73 inhibited the BIR2 (second baculovirus IAP
repeat) domain (BIR2 IC50 = 0.039 lM, BIR3 IC50 = 3.06 lM)
potently with adequate PK proﬁle for further in vivo studies.79 Spi-
rocycle 74 is an orally available inhibitor of glycogen synthase
kinase 3b (GSK-3b) (IC50 = 36 nM) with a signiﬁcant dose-depen-
dent plasma glucose lowering effect after the oral glucose toler-
ance test.80
Summary and perspective: The most utilized spiro ring systems
reported over the last three years involve ﬁve and six membered
rings (Figs. 5–10). Spiro ring systems have been successfully incor-
porated into ligands of GPCRs (e.g., 1, 2, 11–13, 30, 41, 42) and
other receptors, enzyme inhibitors (kinases (e.g., 28, 31, 33), aspar-
tyl proteases renin (52) and BACE1 (16, 17, 18, 43–47), epoxide
hydrolase (67) etc.) and protein–protein interaction inhibitors
(21–26). The presence of a spiro ring fusion tends to impose con-
formational restriction on a molecule. If the spiro ring lies in the
periphery of a molecule, the conformational impact is rather lim-
ited. However, a centrally situated spiro ring signiﬁcantly rigidiﬁes
the compound. In a number of cases, spiro rings were probably
introduced mainly to provide novelty. In such cases, the spiro rings
tend to be in the periphery of the molecules such as in 4, 15, and 32
and the small spiro ring can often be replaced by a geminal dialkyl
group (e.g., geminal dimethyl) without causing signiﬁcant confor-
mational perturbation. For instance, in 15, the cyclobutane ring
can be replaced by geminal dimethyl with a resulting IC50 of
0.9 nM.20 For BACE1 inhibitors 43, 44, 45, 46, and 47, the spiro ring
is crucial for presenting the basic moiety of each inhibitor to the
active site catalytic Asp dyad.21
When a ligand binds to a protein, the bound conformation is
usually not identical to the low energy conformation of the free
ligand in solution; the energy difference between those two con-
formations is referred to as strain energy.81 If the dominant confor-
mation of the free ligand is the same as the bound conformation,
the entropic penalty is alleviated upon protein–ligand complex for-
mation and the ligand binding afﬁnity is enhanced due to reduced
strain energy.82 Constraining the free ligand conformation to the
bound conformation by cyclization has been widely applied, and
in one extreme case, a free energy difference of 3.6–5.6 kcal/mol
was reported.82 When used appropriately, spiro cyclization pro-
vides an excellent way to enforce the desired conformation for
ligand–protein binding; we may expect to see more exampleswhere this tactic has been employed in the future. Introduction
of conformational restriction by ring formation, including spiro
ring formation, can not only modulate binding potency and speci-
ﬁcity, but also potentially improve bioavailability and metabolic
stability.83 Furthermore, conformational restriction may reduce
off-target activities. The fraction of sp3 carbons (Fsp3, ratio of num-
ber of sp3 hybridized carbons and total carbon count in a molecule)
and chiral carbon count have been used as descriptors of molecular
complexity.4c,d Interestingly, the Fsp3 descriptor not only appears
to correlate with the probability of a compound progressing suc-
cessfully from discovery, through clinical testing, to becoming a
drug, but also correlates with compound solubility.4c Furthermore,
increasing complexity also reduces promiscuity and P450 inhibi-
tion.4d Spiro-ring fusion provides a useful method of increasing
molecular complexity and may offer greater beneﬁt than introduc-
tion of ﬂat rings.
With the recent advances in synthetic routes to spiro building
blocks14,84–86 and the interest in fragments with greater three-
dimensionality,87 more bioactive compounds containing spiro
rings will be exploited in drug discovery. Even though all of the
compounds discussed so far contain only one spiro element, in
principle more than one spiro ring system can be incorporated into
a drug molecule.88
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